VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 29, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(SRBCF)(ZSB.F) is pleased to announce the signing of a Letter of Intent (LOI) to create a collaboration with Cincinnati Children's Hospital Medical Center. The goal of the collaboration is to create a novel skin care technology by combining Sirona Biochem's patented cell preservation glycoprotemim with Cincinnati Children's patented synthetic vernix technology.
"Cincinnati Children's Hospital Medical Center is a world leader in discovery of innovative therapeutic treatments and technology," said Neil Belenkie, CEO of Sirona Biochem. "We are proud to be developing a partnership where our two unique technologies will be combined with the intent of creating industry-leading skin therapies with potential for multiple applications."
"We are excited to collaborate with Sirona Biochem and their team of experts to explore the potential of combining our two technologies," said Niki Robinson, PhD, assistant vice president of Cincinnati Children's Center for Technology Commercialization. "This is an important step in ensuring our technology enters the market and is ultimately positioned to improve patient outcomes."
About Cincinnati Children's Hospital Medical Center
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2012 Best Children's Hospitals ranking. It is ranked #1 for neonatology and in the top 10 for all pediatric specialties. Cincinnati Children's is one of the top two recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at www.cincinnatichildrens.org.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic and pharmaceutical use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit: www.sironabiochem.com.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.